Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Research Funding › Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

Sep 29, 2020
|
staff reporter

NEW YORK – Fluidigm disclosed on Monday that it has finalized a contract with the National Institutes of Health related to the production of its microfluidics-based molecular test for SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

What's Popular?

In PCR

  1. UPDATE: Biocartis, Exact Sciences Terminate Oncotype DX Agreement

  2. GenMark Q3 Revenues More Than Double on Respiratory Panel Sales

  3. Moving From Reagents Supplier to Test Developer, Meridian Bio Expands Role During COVID-19 Pandemic

    Premium

  4. Biodesix Prices $72M IPO

  5. Agena Bioscience Gets FDA Emergency Use Authorization for MassArray Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.